Results 211 to 220 of about 224,203 (310)

The hematopoietic stem cells supportive megakaryocytes as shapers of the bone marrow niche. [PDF]

Eur J Histochem
Arciprete F, Velardi V, Verachi P, Carta C, Di Virgilio A, Roberti V, Vivacqua G, Rana R, Zingariello M.   +8 more
europepmc   +1 more source

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation

Clinical Pharmacology &Therapeutics, EarlyView.
The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix, Sam Mostafa, Amin Rostami‐Hodjegan, Thomas M. Polasek, Carl M. J. Kirkpatrick   +4 more
wiley   +1 more source

Correction to "Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early-life <i>DNMT3A</i> mutations". [PDF]

Hemasphere
europepmc   +1 more source

Functional correction and genome integrity with duplex base editing of β-thalassemic hematopoietic stem cells. [PDF]

Genome Biol
Papaioannou NY, Patsali P, Klermund J, Papasavva PL, Andrieux G, Koniali L, Naiisseh B, Christou S, Sitarou M, Kleanthous M, Cathomen T, Lederer CW.   +11 more
europepmc   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Dietary restriction mitigates 5-fluorouracil-induced thrombocytopenia in aged mice via mitochondrial potentiation in hematopoietic stem cells and megakaryocyte progenitors. [PDF]

Stem Cell Reports
Qiu X, Tang D, Lin J, Chen Z, Qiu R, Wang Q, He S, Zhang S, Zhan Q, Tao Z, Zhang L, Tao S.   +11 more
europepmc   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Hematopoietic stem cells VI [result of a Conference Entitled Sixth International Symposium and Workshop on Hematopoietic Stem Cells, held on September 14 - 16, 2006, in Tübingen, Germany]

, 2007
Kanz, Lothar 1951-, International Symposium and Workshop on Hematopoietic Stem Cells 2006 Tübingen   +1 more
core  

In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs. [PDF]

Blood Adv
Karimzadeh A, Kim R, Garcia V, Florea M, Peacker BL, Kobayashi S, Watkins D, Messemer K, Zeng J, Bauer DE, Serwold T, Wagers AJ.   +11 more
europepmc   +1 more source

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Busulfan's narrow therapeutic index and high pharmacokinetic (PK) variability warrant investigation of its exposure–toxicity relationship. We retrospectively analyzed 334 pediatric and young adult patients who underwent allogeneic hematopoietic stem cell transplantation at Seoul National University Children's Hospital between 2009 and 2020 and received
Sungyeun Bae, Jung Yoon Choi, Kyung Taek Hong, Bo Kyung Kim, Hyun Jin Park, Kyung‐Sang Yu, Su‐jin Rhee, Hyoung Jin Kang   +7 more
wiley   +1 more source